1Watanabe Y, Kawai K, Ohashi S, et al. Structure - activity relationships of glucagon - like peptide - ( 7 - 36 ) amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMPproduction in RINm5F cells. J Endocrinol 1994; 140 : 45.
2Sugiyama K, Manaka H, Kato T, et al. Stimulation of truncated glucagon - like peptide - Ⅰ release from isolated perfused caninc ilcum by glucose absorption. Digestion 1994;55:24.
3Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma form uremic patients. J Clin Endocrinol Metab 1992; 74: 379.
4Deacon CF, Nauck A, Nielsen - Toft, et al. Both subcutaneously and intravenously administered glucagon - like peptied - Ⅰ are rapidly degraded from the NH2 - terminus in type 2 diabetic patients and in healthy subjects.Diabetes 1995;44:1126.
5Layer P, Holst JJ. GLP - Ⅰ: a humoral mediaror of the ileal brake in humans? Digestion 1993;54:385.
6Gutniak M, Rskov C, Holst JJ, et al. Antideiabto - genic efect of glucagon - like peptide- Ⅰ(7 - 36)amide in normal subjccts and patients with diabetes mcllitus. N Engl J Med 1992; 326:1316.
7Gutniak M, Juntti BL, Guenifi A, et al. Glucagon - like peptide- Ⅰ enhances the insulinotropic effects of glibenclamidw in NIDDM patients and in perfused rat pancreas. Diabetes Care 1996;19:857.
